论文部分内容阅读
目的探讨含铂两药方案治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法回顾性分析2008年7月至2010年12月收治的54例老年Ⅲ期非小细胞肺癌患者的临床资料,随机分为两组,每组27例,A组采用卡铂联合多西紫杉醇治疗,B组采用卡铂联合吉西他滨治疗。结果 B组患者治疗后总有效率为59.3%(16/27),与A组总有效率29.6%(8/27)比较,差异有统计学意义(P<0.05),且B组患者的1年生存率(48.2%)比A组的1年生存率(22.2%)高,组间差异有统计学意义(P<0.05),但2年生存率差异无统计学意义。另外,含铂两药方案的不良反应均表现在脊髓抑制方面。结论铂类联合细胞毒剂的两药方案一线治疗老年Ⅲ期非小细胞肺癌疗效较好,但应控制好剂量以减轻患者的不良反应。
Objective To investigate the clinical efficacy and adverse reactions of two platinum-containing regimens in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Methods The clinical data of 54 elderly patients with stage Ⅲ non-small cell lung cancer admitted to our hospital from July 2008 to December 2010 were retrospectively analyzed. The patients were randomly divided into two groups (n = 27 in each group). Patients in group A received carboplatin plus docetaxel , B group treated with carboplatin and gemcitabine. Results The total effective rate of group B was 59.3% (16/27) after treatment, which was significantly different from that of group A (29.6%, 8/27) (P <0.05), and group B The annual survival rate (48.2%) was higher than that in group A (22.2%). The difference between the two groups was statistically significant (P <0.05). However, the difference in 2-year survival rate was not statistically significant. In addition, the adverse reactions of the two platinum-containing regimens are manifested in spinal suppression. Conclusions The two-drug regimen of platinum combined with cytotoxic agents is superior to the first-line treatment of advanced stage Ⅲ non-small cell lung cancer. However, good dosage should be controlled to reduce adverse reactions in patients.